This variance or decrease in PSMA expressions affects the patient selection process and subsequently results in low absorbed doses in individual tumor lesions, ultimately reducing the therapeutic efficacy of [177Lu]Lu-PSMA therapy [40,43]. The gene discussed is FOLH1; the disease is neoplasm.